SCHEMBL29637567

SCHEMBL29637567

CC(C)COC(=O)[C@H](C)NP(=O)(Oc1c(F)c(F)c(F)c(F)c1F)Oc1cccc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTN3A1 O00481 6/20 0.38
▸ OGG1 O15527 1/20 0.36
▸ CYP2D6 P10635 4/20 0.35
▸ CYP1A2 P05177 3/20 0.35
▸ ADRB2 P07550 3/20 0.35
▸ ADRB1 P08588 3/20 0.35
▸ SLC6A4 P31645 3/20 0.35
▸ HTR2B P41595 3/20 0.35
▸ SIGMAR1 Q99720 3/20 0.35
▸ NR2E1 Q9Y466 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ ADRB3 P13945 2/20 0.35
▸ HTR2A P28223 2/20 0.35
▸ HTR2C P28335 2/20 0.35
▸ SCN1A P35498 2/20 0.35
▸ HTR6 P50406 2/20 0.35
▸ SLC10A1 Q14973 2/20 0.35
▸ SCN2A Q99250 2/20 0.35
▸ SCN3A Q9NY46 2/20 0.35
▸ MAPK1 P28482 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25216399 0.91 BTN3A1 (0.35) BTN3A1OGG1CYP2D6CYP1A2ADRB2
SCHEMBL25268253 0.91 BTN3A1 (0.35) BTN3A1OGG1CYP2D6CYP1A2ADRB2
SCHEMBL29895522 0.91 BTN3A1 (0.41) BTN3A1OGG1ALDH1A1HTTLMNA
SCHEMBL28986476 0.91 BTN3A1 (0.41) BTN3A1OGG1ALDH1A1HTTLMNA
SCHEMBL23044633 0.89 MEN1 (0.39) BTN3A1OGG1NR2E1ALDH1A1MAPK1
SCHEMBL20833545 0.88 BTN3A1 (0.42) BTN3A1ALDH1A1MAPK1SMN1; SMN2LMNA
SCHEMBL20587649 0.88 BTN3A1 (0.42) BTN3A1ALDH1A1MAPK1SMN1; SMN2LMNA
SCHEMBL22065060 0.88 BTN3A1 (0.42) BTN3A1ALDH1A1MAPK1SMN1; SMN2LMNA
SCHEMBL13469494 0.88 HTT (0.39) BTN3A1OGG1ALDH1A1MAPK1HSD17B10
SCHEMBL30435500 0.88 BTN3A1 (0.42) BTN3A1ALDH1A1MAPK1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112513061-B 4' -Thio-nucleotides and-nucleoside prodrugs for treating cancer 南方研究院 2025-01-24 — — CN disclosed
US-20240116972-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS SOUTHERN RES INST (US) 2024-04-11 — — US disclosed
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections SOUTHERN RESEARCH INSTITUTE (US) 2024-01-02 — — US disclosed
EP-4262812-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS Southern Research Institute (US) 2023-10-25 — — EP disclosed
EP-4209498-A1 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER Southern Research Institute (US) 2023-07-12 — — EP disclosed
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS OREGON HEALTH AND SCIENCE UNIVERSITY 2022-06-30 — — US disclosed
WO-2022133323-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS MTAP, GALE, TPMT BTN3A1 3911/4885OGG1 257/4885CYP2D6 118/4885
US-20240116972-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS MTAP, GALE, TPMT BTN3A1 3911/4885OGG1 257/4885CYP2D6 118/4885
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections MTAP, GALE, TPMT BTN3A1 3911/4885OGG1 257/4885CYP2D6 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback